Factors associated with naloxone availability and dispensing through Michigan’s pharmacy standing order

ABSTRACT

Background: Pharmacy standing order policies allow pharmacists to dispense naloxone, thereby increasing access to naloxone.

Objectives: To describe pharmacy standing order participation and associations of pharmacy and community characteristics that predict naloxone availability and dispensing across eight counties in Michigan.

Methods: We conducted a telephone survey of 662 standing order pharmacies with a response rate of 81% (n = 539). Pharmacies were linked with census tract-level demographics, overdose fatality rates, and dispensing data. County maps were created to visualize pharmacy locations relative to fatality rates. Regression models analyzed associations between pharmacy type, neighborhood characteristics, fatality rates, and these outcomes: naloxone availability, having ever dispensed naloxone, and counts of naloxone dispensed.

Results: The prevalence of standing order pharmacies was 54% (n = 662/1231). Maps revealed areas with higher fatality rates had fewer pharmacies participating in the standing order or lacked any pharmacy access. Among standing order pharmacies surveyed, 85% (n = 458/539) had naloxone available and 82% had ever dispensed (n = 333/406). The mean out-of-pocket cost of Narcan_® was $127.77 (SD: 23.93). National chains were more likely than regional chains to stock naloxone (AOR = 3.75, 95%CI = 1.77, 7.93) and to have ever dispensed naloxone (AOR 3.02, 95%CI = 1.21,7.57). Higher volume of naloxone dispensed was associated in neighborhoods with greater proportions of public health insurance (IRR = 1.38, 95%CI = 1.21, 1.58) and populations under 44 years old (IRR = 1.24, 95%CI = 1.04, 1.48). There was no association with neighborhood overdose fatality rates or race in regression models.

Conclusion: As deaths from the opioid epidemic continue to escalate, efforts to expand naloxone access through greater standing order pharmacy participation are warranted.

KEYWORDS:

• Pharmacy
• naloxone
• overdose
• standing order
• Michigan

Disclosure statement

Dahlem receives royalties as a co-inventor of Rapid Assessment for Adolescent Preventive Services. Brummett has received funding personally from Heron Therapeutics, Vertex Pharmaceuticals, Benter Foundation, and Alosa Health, and provides medicolegal expert testimony. All other authors report no conflicts of interest and no financial relationships with commercial entities.

Supplementary material

Supplemental data for this article can be accessed on the publisher’s website

Additional information

Funding

This project was supported by a grant from SAMHSA (SOR+ E20203204-00) and the University of Michigan Precision Health Initiative.